LIPO: Lipella Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5.02
Enterprise Value ($M) 1.73
Book Value ($M) 3.14
Book Value / Share 0.45
Price / Book 1.60
NCAV ($M) 3.00
NCAV / Share 0.43
Price / NCAV 1.68

Profitability (mra)
Return on Invested Capital (ROIC) -1.41
Return on Assets (ROA) -1.00
Return on Equity (ROE) -1.21

Liquidity (mrq)
Quick Ratio 8.90
Current Ratio 8.90

Balance Sheet (mrq) ($M)
Current Assets 3.43
Assets 3.58
Liabilities 0.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.45
Operating Income -4.75
Net Income -4.62

Cash Flow Statement (mra) ($M)
Cash From Operations -3.15
Cash from Investing -0.01
Cash from Financing 1.34

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
03-19 13D/A Kaufman Jonathan H 21.00 9.00
03-15 13D/A Chancellor Michael B 20.00 10.36
02-07 13G/A Gruber Michele 5.50 3.30
01-25 13G/A Huang Leaf 9.60 0.00
01-03 13G Sabby Management, Llc 9.99

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023, or ☐ TRANSITION
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023, or ☐ TRANSITION REPO
2023-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023, or ☐ TRANSITION REP

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-18 1,355 2,204 61.48
2024-04-17 6,043 26,069 23.18
2024-04-16 867 12,953 6.69
2024-04-15 3,387 15,086 22.45

(click for more detail)

Similar Companies
LFVN – LifeVantage Corporation LGVN – Longeveron Inc.
LIFE – aTyr Pharma, Inc. LIXT – Lixte Biotechnology Holdings, Inc.
LPCN – Lipocine Inc.


Financial data and stock pages provided by
Fintel.io